老年成人肥胖药物治疗:老年医学5Ms框架下的安全与以患者为中心的处方
本文聚焦经肠源性激素通路起效的肥胖药物(GLP-1受体激动剂、GIP/GLP-1双受体激动剂及在研的三受体激动剂),指出这类药物在体重管理和血糖控制及心肾代谢方面获益明确,但用于老年成人需格外审慎。作者结合衰弱、认知障碍、糖皮质激素使用和手术规划等老年医学常见情境,提出以老年医学5Ms框架(Mind、Mobility、Medications、Multicomplexity、Matters Most)组织处方决策,并强调抵抗训练、充足蛋白摄入与持续功能监测等生活方式协同干预。
要点
- 老年成人使用此类药物需警惕瘦体重丢失、衰弱与肌少症风险
- 脱水、营养不良、围手术期误吸及停药后以脂肪为主的体重反弹在老年中后果更重
- 处方应结合5Ms框架,并配合抵抗训练、蛋白摄入与功能监测
核心结论
- 经肠源性激素通路的肥胖药物对多种健康情况有显著获益,但老年成人使用需加强审视以平衡获益与风险。
研究设计与样本
- 本文为面向临床的框架性文章,基于老年医学常见患者情境(衰弱、认知障碍、糖皮质激素使用、手术规划)提出处方路径,未报告原始研究设计与样本量。
主要发现
- 大型临床试验证据提示,相当比例的药物相关减重可能伴随瘦体重丢失,对老年成人构成潜在风险。
- 在老年成人中后果可能更大的其他不良反应包括脱水、营养不良、围手术期误吸以及停药后以脂肪为主的体重反弹。
关键数值与推荐
- 作者将处方建议整合于老年医学5Ms框架(Mind、Mobility、Medications、Multicomplexity、Matters Most)之中。
- 生活方式协同干预被列为接受此类治疗老年成人的必要组成部分,尤其是抵抗训练、充足蛋白摄入与持续功能监测。
临床怎么用
- 在老年成人中启动或继续此类药物前,应结合5Ms框架评估认知、活动能力、合并用药、多重共病与患者最看重的事项。
- 处方同时应配套抵抗训练、充足蛋白摄入和持续功能监测,并在围手术期与停药计划中提前评估误吸与体重反弹风险。
局限性
- 本文为临床导向的框架性文章,未报告原始研究数据、样本量或定量阈值;作者指出年龄分层临床试验及常规纳入体成分与身体功能结局是未来研究优先方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity medications that act through gut-derived hormonal pathways include glucagon-like peptide-1 receptor agonists (GLP-1), dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GLP-1/GIP), and emerging triple glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor agonists. These therapies are increasingly prescribed for weight management and glycemic control, as well as for their cardiometabolic and renal benefits. While these medications offer substantial benefits to patients across multiple health conditions, their use in older adults warrants heightened scrutiny. Older adults face increased risks of sarcopenia and frailty, and evidence from major clinical trials suggests that a substantial proportion of medication-associated weight loss agents may result in loss of lean mass, potentially posing risks for this population. Other adverse effects that may be more consequential in older adults include dehydration, malnutrition, perioperative aspiration, and fat-predominant weight regain after discontinuation. This paper provides a clinically oriented framework to guide prescribing decisions for older adults. Drawing on patient scenarios from common geriatric contexts, including frailty, cognitive impairment, glucocorticoid use, and surgical planning, we propose prescribing approaches that optimize therapeutic benefits while mitigating potential harms. We integrate these recommendations within the Geriatrics 5Ms Framework (Mind, Mobility, Medications, Multicomplexity, and Matters Most) to contextualize treatment within geriatrics practice. Lifestyle co-interventions, particularly resistance training, adequate protein intake, and ongoing functional monitoring, emerge as essential components for older adults receiving these therapies. We also discuss identifying priority areas for future research, including age-stratified clinical trials and the routine inclusion of body composition and physical function outcomes.
引用
- Wisdom, Goldlist, Lieber, et al. Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing. J Am Geriatr Soc. 2026. PMID: 42952307. doi:10.1111/jgs.70769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。